Such is the case for trastuzumab treatment and soluble Her2/neu ECD in breast cancer [47,48], for soluble EGFR during chemotherapy in breast cancer [49], and for soluble c-kit in response to imatinib treatment in gastrointestinal tumor (GIST) patients [50]. Here, EGFR is linked to digestive system neoplasm.